BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20842456)

  • 1. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.
    Hearle N; Damato BE; Humphreys J; Wixey J; Green H; Stone J; Easton DF; Houlston RS
    Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):458-62. PubMed ID: 12556369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.
    Soufir N; Bressac-de Paillerets B; Desjardins L; Lévy C; Bombled J; Gorin I; Schlienger P; Stoppa-Lyonnet D
    Br J Cancer; 2000 Feb; 82(4):818-22. PubMed ID: 10732752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
    Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
    Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
    Monnerat C; Chompret A; Kannengiesser C; Avril MF; Janin N; Spatz A; Guinebretière JM; Marian C; Barrois M; Boitier F; Lenoir GM; Bressac-de Paillerets B
    Fam Cancer; 2007; 6(4):453-61. PubMed ID: 17624602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
    Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
    Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients.
    Cebulla CM; Binkley EM; Pilarski R; Massengill JB; Rai K; Liebner DA; Marino MJ; Singh AD; Abdel-Rahman MH
    Ophthalmic Genet; 2015 Jun; 36(2):126-31. PubMed ID: 25687217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
    Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
    Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
    Ming Z; Lim SY; Rizos H
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutation of ARF in a melanoma kindred.
    Hewitt C; Lee Wu C; Evans G; Howell A; Elles RG; Jordan R; Sloan P; Read AP; Thakker N
    Hum Mol Genet; 2002 May; 11(11):1273-9. PubMed ID: 12019208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
    Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
    Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
    Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
    Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma.
    Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB
    Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The INK4a-ARF locus: role in the genetic predisposition to familial melanoma and in skin carcinogenesis].
    Soufir N; Basset-Seguin N
    Bull Cancer; 2001 Nov; 88(11):1061-7. PubMed ID: 11741799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
    Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.